Drug
Tenofovir alafenamide fumarate
Tenofovir alafenamide fumarate is a pharmaceutical drug with 4 clinical trials. Currently 2 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
2(50%)
Phase Distribution
Ph not_applicable
3
75%
Ph phase_4
1
25%
Phase Distribution
0
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 4Post-market surveillance
1(25.0%)
N/ANon-phased studies
3(75.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(2)
Other(2)
Detailed Status
unknown2
Recruiting2
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
N/A
Most Advanced
Phase 4
Trials by Phase
Phase 41 (25.0%)
N/A3 (75.0%)
Trials by Status
unknown250%
recruiting250%
Recent Activity
2 active trials
Showing 4 of 4
recruitingnot_applicable
Nucleoside (Acid) Analogues Treatment in Patients With Normal ALT and Positive HBVDNA.
NCT04231565
recruitingnot_applicable
TAF (Tenofovir Alafenamide) for Preventing Progression of Liver Disease in Non-cirrhotic Chronic HBV Infection With Normal ALT and Low Viral Load.
NCT05195450
unknownnot_applicable
The Efficacy and Safety of TAF vs Other NAs in Patients With LVL
NCT04501224
unknownphase_4
TAF Switch Study in Hepatitis B Monoinfection
NCT02957994
Clinical Trials (4)
Showing 4 of 4 trials
NCT04231565Not Applicable
Nucleoside (Acid) Analogues Treatment in Patients With Normal ALT and Positive HBVDNA.
NCT05195450Not Applicable
TAF (Tenofovir Alafenamide) for Preventing Progression of Liver Disease in Non-cirrhotic Chronic HBV Infection With Normal ALT and Low Viral Load.
NCT04501224Not Applicable
The Efficacy and Safety of TAF vs Other NAs in Patients With LVL
NCT02957994Phase 4
TAF Switch Study in Hepatitis B Monoinfection
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4